BiotechTube
GENinCode

GENinCode

Oxford, United Kingdom· Est.
genincode.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

GENinCode is a commercial-stage diagnostics company focused on genomic risk assessment for cardiovascular disease (CVD). Founded in 2014 and based in Oxford, UK, the company leverages a proprietary platform integrating polygenic risk scores (PRS), monogenic analysis, and clinical algorithms to provide physicians with tools for early intervention. It has secured key partnerships, including with the NHS and Thermo Fisher Scientific, and has obtained regulatory approvals such as New York State clinical test approval for its lead product. The company is positioning itself at the intersection of preventive cardiology and personalized medicine.

Cardiovascular DiseaseMetabolic Diseases

Technology Platform

Proprietary platform combining polygenic risk scores (PRS), monogenic analysis for inherited disorders, and clinical risk algorithms enhanced by artificial intelligence (AI) to provide integrated cardiovascular and metabolic disease risk assessment.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The growing shift towards preventive healthcare and personalized medicine creates a massive addressable market for genetic risk assessment.
Partnerships with large public health systems like the NHS provide a direct route to population-scale deployment and validation.
Expansion into related indications (metabolic disease, oncology) leverages the core platform for new revenue streams.

Risk Factors

Securing consistent reimbursement from payers is a major hurdle, requiring robust health-economic data.
The competitive landscape for polygenic risk scores is intensifying with larger diagnostic firms and startups.
Clinical adoption depends on inclusion in treatment guidelines, which requires ongoing high-impact validation studies.

Competitive Landscape

GENinCode competes in the emerging market for clinical polygenic risk scores (PRS) against other dedicated genomics firms (e.g., Allelica, Myriad Genetics' riskScore) and the in-house development efforts of large clinical labs (Quest, LabCorp). Its differentiation lies in the integrated combination of polygenic and monogenic risk with clinical algorithms. It also faces competition from traditional risk assessment tools based solely on clinical factors.

More companies in United Kingdom →